<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Nephrol</journal-id><journal-id journal-id-type="publisher-id">IJN</journal-id><journal-title-group><journal-title>Indian Journal of Nephrology</journal-title></journal-title-group><issn pub-type="ppub">0971-4065</issn><issn pub-type="epub">1998-3662</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20535265</article-id><article-id pub-id-type="pmc">2878405</article-id><article-id pub-id-type="publisher-id">IJN-50-15</article-id><article-id pub-id-type="doi">10.4103/0971-4065.62090</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: A prospective study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jalal</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Sofi</surname><given-names>F. A.</given-names></name><xref ref-type="aff" rid="AF0002">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Abass</surname><given-names>S. M.</given-names></name><xref ref-type="aff" rid="AF0002">1</xref></contrib><contrib contrib-type="author"><name><surname>Alai</surname><given-names>M. S.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Bhat</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="AF0003">2</xref></contrib><contrib contrib-type="author"><name><surname>Rather</surname><given-names>H. A.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Lone</surname><given-names>N. A.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Siddiqi</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="AF0004">3</xref></contrib></contrib-group><aff id="AF0001">Department of Cardiology, Sher-i-Kashmir Institute of Medical Sciences, (SKIMS), Soura, Srinagar, Kashmir, India</aff><aff id="AF0002"><label>1</label>Department of Internal Medicine, Sher-i-Kashmir Institute of Medical Sciences, (SKIMS), Soura, Srinagar, Kashmir, India</aff><aff id="AF0003"><label>2</label>Department of Nephrology, Sher-i-Kashmir Institute of Medical Sciences, (SKIMS), Soura, Srinagar, Kashmir, India</aff><aff id="AF0004"><label>3</label>Department of Immunology and Molecular Medicine, Sher-i-Kashmir Institute of Medical Sciences, (SKIMS), Soura, Srinagar, Kashmir, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Fayaz Ahmad Sofi, Department of Internal Medicine, Sher-i-Kashmir Institute of Medical Sciences, (SKIMS), Soura, Srinagar-190 011, Kashmir, India. E-mail: <email xlink:href="fayazkanjwal@rediffmail.com">fayazkanjwal@rediffmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2010</year></pub-date><volume>20</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><permissions><copyright-statement>&#x000a9; Indian Journal of Nephrology</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Microalbuminuria can be present in 25&#x02013;100% of patients with essential hypertension and is associated with increased incidence of cardiovascular events. Our goal was to evaluate the effect of a commonly used calcium channel blocker, amlodipine, and an angiotensin converting enzyme inhibitor, lisinopril on urinary albumin excretion in patients with mild to moderate essential hypertension. We screened 324 patients with essential hypertension for microalbuminuria and documented it in 120 patients. These 120 patients with microalbuminuria were randomly divided into two groups of 60 each, matched for age, sex, arterial pressure, creatinine clearance, and urinary albumin excretion so as to receive amlodipine or lisinopril. We prospectively measured their urinary albumin excretion and creatinine clearance prior to treatment and, four and eight weeks after treatment with amlodipine or lisinopril. Mean arterial pressure (mean &#x000b1; SD) at baseline, after four weeks, and after eight weeks was 113.01 &#x000b1; 4.38,104.93 &#x000b1; 3.12, and 98.89 &#x000b1; 1.75&#x02009;mmHg (<italic>P</italic> &#x0003c; 0.0000); and 114.13 &#x000b1; 7.11, 106.52 &#x000b1; 3.50, and 100.89 &#x000b1; 2.80&#x02009;mmHg (<italic>P</italic> &#x0003c; 0.0000) in amlodipine and lisinopril groups, respectively. Urinary albumin excretion (mean &#x000b1; SEM) at baseline, after four, and after eight weeks was 79.30 &#x000b1; 3.74, 62.03 &#x000b1; 3.61, and 52.02 &#x000b1; 3.05 (<italic>P</italic> &#x0003c; 0.0000); and 73.96 &#x000b1; 4.10, 72.39 &#x000b1; 3.74, 66.12 &#x000b1; 3.94 (<italic>P</italic> = 0.1742) in lisinopril and amlodipine groups, respectively. Lisinopril but not amlodipine, reduced the urinary albumin excretion significantly despite their similar antihypertensive efficacy. The clinical and prognostic significance of these observations need to be established.</p></abstract><kwd-group><kwd>Angiotensin converting enzyme inhibitors</kwd><kwd>calcium channel blockers</kwd><kwd>hypertension</kwd><kwd>microalbuminuria</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>The conventional methods of detecting renal damage in hypertension which include the measurement of blood urea nitrogen and creatinine, and proteinuria, are relatively insensitive, and only show abnormalities when the disease process is fairly advanced. Essential hypertension (EHT) produces clinical proteinuria and significant reduction in renal function in 5-15% of patients.[<xref ref-type="bibr" rid="CIT1">1</xref>] There has recently been considerable interest in the quantitative measurement of albuminuria to detect the subtle effects of hypertension on the kidneys. The term microalbuminuria was first used to describe the subclinical elevation of urinary albumin in patients with diabetic nephropathy. The advent of more sensitive method to quantitate the urinary albumin excretion (UAE) has unfolded higher frequency (25-100%) of microalbuminuria in patients with hypertension than in normotensive population.[<xref ref-type="bibr" rid="CIT2">2</xref>&#x02013;<xref ref-type="bibr" rid="CIT6">6</xref>]</p><p>Several epidemiological studies have shown that proteinuria as well as microalbuminuria are independent predictors of cardiovascular morbidity and mortality in patients with EHT.[<xref ref-type="bibr" rid="CIT7">7</xref>] The hypothesis that reduction of UAE during long term antihypertensive treatment may induce an improvement in the cardiovascular complications associated with EHT, is still under investigation. The angiotensin converting enzyme (ACE) inhibitors have been known to induce a regression of the proteinuria both in normotensive and hypertensive patients with diabetic renal illness[<xref ref-type="bibr" rid="CIT8">8</xref>] and in hypertensive patients with chronic renal failure.[<xref ref-type="bibr" rid="CIT9">9</xref>] Calcium Channel Blockers (CCB) have only been evaluated recently with regard to their anti-proteinuric effects in humans with diabetes mellitus. Numerous short term studies have been performed in the past few years to assess the effects of different classes of CCB in the diabetes[<xref ref-type="bibr" rid="CIT10">10</xref>&#x02013;<xref ref-type="bibr" rid="CIT14">14</xref>] and hypertension.[<xref ref-type="bibr" rid="CIT15">15</xref><xref ref-type="bibr" rid="CIT16">16</xref>] However, these studies revealed divergent results.</p><p>Since 25% of patients with end-stage renal disease (ESRD) have hypertension as the primary diagnosis[<xref ref-type="bibr" rid="CIT1">1</xref>] and moreover, microalbuminuria reflects endothelial damage which has been associated with increased cardiovascular mortality and morbidity, it becomes of paramount importance to study the effects of commonly used antihypertensive drugs like ACE inhibitor lisinopril and CCB-amlodipine on microalbuminuria and renal function in hypertension.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>We screened 324 patients with EHT, who attended General Medicine and Cardiology out-patient clinics of tertiary care hospital in north India. Hypertensive patients were included in the study if they met the following criterion.</p><list list-type="roman-lower"><list-item><p>Diastolic blood pressure (DBP) persistently between 90 and 100 mmHg on three successive visits to the outpatient clinic.</p></list-item><list-item><p>UAE was between 30-300 mg/24 hrs; we chose the level of 30 mg/24 hrs to define the presence of microalbuminuria because in a previous study it was shown that all the normal subjects had UAE below this value.[<xref ref-type="bibr" rid="CIT1">2</xref>]</p></list-item><list-item><p>A creatinine clearance (Clcr) level greater than 80 ml/ min/l.73 m<sup>2</sup> in three different measurements.</p></list-item><list-item><p>No antihypertensive therapy in the past.</p></list-item></list><p>We enrolled 120 patients who met the above criteria. Females on birth control pills were excluded from the study. The diagnosis of secondary hypertension was excluded with regular laboratory analysis. Patients with clinical or laboratory evidence of hepatic, renal, thyroid or any other major illness like diabetes mellitus were excluded. This group of 120 patients was randomly divided into two subgroups of 60 each matched for age, sex, arterial pressure, Clcr and UAE. One subgroup received an ACE inhibitor lisinopril, other received a CCB amlodipine. The dose of drugs was gradually increased to maximum desirable dose.Aimed target blood pressure was &#x0003c;130/80 mmHg. The administration of the drugs was open labelled, and these drugs were administered at 8 am daily except on the day of study when the drugs were given only after blood pressure measurement and drawing of sample. 24-hour urine was collected before the start of the study and after four and eight weeks of treatment to measure UAE, creatinine, sodium and potassium. At baseline, and after four and eight weeks of treatment during the study creatinine clearance, serum sodium and potassium were also measured. Blood and urine creatinine were estimated by autoanalyser. Urinary albumin excretion was estimated by an immunoturbidometry method using an automated Biochemistry Analyzer (Hitachi704).</p><p>Statistical analysis was performed by using statistical package for social science (SPSS) version 11.5 for PC windows. A 2-tailed <italic>P</italic> value of &#x0003c; 0.05 was taken as statistically significant.</p></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>Patients on amlodipine or lisinopril did not differ with respect to their age, sex, BMI, smoking, and severity of HT [<xref ref-type="table" rid="T0001">Table 1</xref>]. Also their baseline laboratory parameters were comparable [<xref ref-type="table" rid="T0002">Table 2</xref>]. The mean daily dose of amlodipin used was 8.04 &#x000b1; 2.06 mg (range, 5&#x02013;10 mg). None of the patients on amlodipine experienced any adverse drug effect. In lisinopril group, mean daily dose of drug used was 8.21 &#x000b1; 1.99 mg (range, 5-10 mg). One patient experienced mild dry cough which did not necessitate to stop the drug. The aimed target blood pressure (&#x0003c;13/80) was achieved in 81 (67.5%) patients (which included 42 (70%) and 39 (65%) in amlodepin and lisinopril group respectively). Baseline systolic (SBP), diastolic (DBP) and mean arterial pressures (MAP) were comparable between amlodipine and lisinopril group [<xref ref-type="table" rid="T0003">Table 3</xref>]. There was significant reduction in SBP, DBP and MAP at 4 and 8 weeks in both the groups (<italic>P</italic> &#x0003c; 0.0000). We observed significant reduction in DBP and MAP after four and eight weeks of therapy in amlodipine group compared to lisinopril group (<italic>P</italic> = 0.0003, 0.025; and 0.01, &#x0003c;0.0001, respectively). However, SBP was comparable between the two groups at four and eight weeks of therapy [<xref ref-type="table" rid="T0003">Table 3</xref>].
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Comparison between clinical characteristics of hypertensive patients on amlodipine and lisinopril</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Amlodipine group N = 60</th><th align="center" rowspan="1" colspan="1">Lisinopril group N = 60</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">55.12 &#x000b1; 4.85</td><td align="center" rowspan="1" colspan="1">53.23 &#x000b1; 6.24</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td align="center" rowspan="1" colspan="1">(48-61)</td><td align="center" rowspan="1" colspan="1">(44-63)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male (%)</td><td align="center" rowspan="1" colspan="1">27 (45)</td><td align="center" rowspan="1" colspan="1">33 (55.55)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female (%)</td><td align="center" rowspan="1" colspan="1">33 (55)</td><td align="center" rowspan="1" colspan="1">27 (45)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m2)</td><td align="center" rowspan="1" colspan="1">24.43 &#x000b1; 3.70</td><td align="center" rowspan="1" colspan="1">25.69 &#x000b1; 4.13</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td align="center" rowspan="1" colspan="1">(20.98-31.56)</td><td align="center" rowspan="1" colspan="1">(18.46-32.87)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (%)</td><td align="center" rowspan="1" colspan="1">33 (55)</td><td align="center" rowspan="1" colspan="1">27 (45)</td><td align="center" rowspan="1" colspan="1">&#x0003e; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male (%)</td><td align="center" rowspan="1" colspan="1">20 (60.60)</td><td align="center" rowspan="1" colspan="1">14 (51.85)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female (%)</td><td align="center" rowspan="1" colspan="1">13 (39.40)</td><td align="center" rowspan="1" colspan="1">13 (48.15)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Severity of hypertension<xref ref-type="table-fn" rid="TF0001">*</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003e; 0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mild (%)</td><td align="center" rowspan="1" colspan="1">16 (26.67)</td><td align="center" rowspan="1" colspan="1">21 (35)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate (%)</td><td align="center" rowspan="1" colspan="1">44 (73.33)</td><td align="center" rowspan="1" colspan="1">39 (65)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>BMI = Body mass index</p></fn><fn id="TF0001"><label>*</label><p>Mild-140-149/90-94; Moderate-150-159/95-100mmHg; Values expressed as mean &#x000b1; SD</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Laboratory characteristics of patients on amlodipine and lisinopril</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Amlodipine group n = 60</th><th align="center" rowspan="1" colspan="1">Lisinopril group n = 60</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (gm/dl)</td><td align="center" rowspan="1" colspan="1">12.14 &#x000b1; 2.02</td><td align="center" rowspan="1" colspan="1">12.25 &#x000b1; 2.01</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(9.8-15.5)</td><td align="center" rowspan="1" colspan="1">(10.4-14.5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bloodglucose (mg/dl)</td><td align="center" rowspan="1" colspan="1">88.11 &#x000b1; 17.95</td><td align="center" rowspan="1" colspan="1">90.33 &#x000b1; 22.93</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(68-110)</td><td align="center" rowspan="1" colspan="1">(66-124)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mg/dl)</td><td align="center" rowspan="1" colspan="1">160.77 &#x000b1; 29.89</td><td align="center" rowspan="1" colspan="1">165.22 &#x000b1; 33.26</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(106-200)</td><td align="center" rowspan="1" colspan="1">(103-200)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Uric acid (mg/dl)</td><td align="center" rowspan="1" colspan="1">4.77 &#x000b1; 0.94</td><td align="center" rowspan="1" colspan="1">4.58 &#x000b1; 0.87</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(3.8-6.4)</td><td align="center" rowspan="1" colspan="1">(3.0-6.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Proteins (gm/dl)</td><td align="center" rowspan="1" colspan="1">7.39 &#x000b1; 0.94</td><td align="center" rowspan="1" colspan="1">7.19 &#x000b1; 0.78</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(5.8-8.5)</td><td align="center" rowspan="1" colspan="1">(5.8-8.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Albumin (gm/dl)</td><td align="center" rowspan="1" colspan="1">4.11 &#x000b1; 0.64</td><td align="center" rowspan="1" colspan="1">4.09 &#x000b1; 0.55</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(3.0-5.1)</td><td align="center" rowspan="1" colspan="1">(3.1-5.0)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Values expressed as mean &#x000b1; SD, unless specified; Figures in parentheses indicate ranges </p></fn></table-wrap-foot></table-wrap><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Baseline systolic, diastolic and mean arterial blood pressure prior to and after four and eight weeks of treatment with amlodipine and lisinopril in hypertensive microalbuminuric patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Baseline</th><th align="left" rowspan="1" colspan="1">4 weeks</th><th align="left" rowspan="1" colspan="1">8 weeks</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SBP (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">149.66 &#x000b1; 10.93</td><td align="center" rowspan="1" colspan="1">139.22 &#x000b1; 9.60</td><td align="center" rowspan="1" colspan="1">131.66 &#x000b1; 6.40</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(140-160)</td><td align="center" rowspan="1" colspan="1">(130-150)</td><td align="center" rowspan="1" colspan="1">(125-142)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">151 &#x000b1; 11.86</td><td align="center" rowspan="1" colspan="1">138 &#x000b1; 7.52</td><td align="center" rowspan="1" colspan="1">132.22 &#x000b1; 7.76</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(142-160)</td><td align="center" rowspan="1" colspan="1">(132-150)</td><td align="center" rowspan="1" colspan="1">(125-140)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c; 0.524</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.444</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.669</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">DBP (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">94.69 &#x000b1; 4.27</td><td align="center" rowspan="1" colspan="1">87.89 &#x000b1; 3.64</td><td align="center" rowspan="1" colspan="1">84 &#x000b1; 2.45</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(90-100)</td><td align="center" rowspan="1" colspan="1">(80-92)</td><td align="center" rowspan="1" colspan="1">(82-90)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">95.63 &#x000b1; 4.87</td><td align="center" rowspan="1" colspan="1">90 &#x000b1; 2.46</td><td align="center" rowspan="1" colspan="1">85.22 &#x000b1; 3.23</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(90-100)</td><td align="center" rowspan="1" colspan="1">(80-92)</td><td align="center" rowspan="1" colspan="1">(84-92)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.267</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.0003</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.025</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MAP (mmHg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">113.01 &#x000b1; 4.38</td><td align="center" rowspan="1" colspan="1">104.93 &#x000b1; 3.12</td><td align="center" rowspan="1" colspan="1">98.89 &#x000b1; 1.75</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(106.67-120)</td><td align="center" rowspan="1" colspan="1">(96.67-111.30)</td><td align="center" rowspan="1" colspan="1">96.33-107.33)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">114.13 &#x000b1; 7.11</td><td align="center" rowspan="1" colspan="1">106.52 &#x000b1; 3.50</td><td align="center" rowspan="1" colspan="1">100.89 &#x000b1; 2.80</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(107.33-120)</td><td align="center" rowspan="1" colspan="1">(97.33-113.33)</td><td align="center" rowspan="1" colspan="1">(97.66-108)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.305</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.01</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> = 0.0000</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as mean &#x000b1; SD; Figures in parentheses indicate range</p></fn></table-wrap-foot></table-wrap><p>Serum creatinine, serum sodium, serum potassium, and urinary sodium, and potassium levels were comparable between amlodipine group and lisinopril group prior to treatement, four and eight weeks after the treatment. These parameters did not change significantly over eight weeks of therapy with amlodipine or lisinopril [<xref ref-type="table" rid="T0004">Table 4</xref>], we did not observe any significant change in Clcr after four and eight weeks of therapy with amlodipine or lisinopril compared to the baseline values [<xref ref-type="table" rid="T0005">Table 5</xref>]. Also comparison of Clcr between two groups did not reveal any significant difference after four and eight weeks of treatment.</p><table-wrap id="T0004" position="float"><label>Table 4</label><caption><p>Effect of amlodipine and lisinopril on various laboratory parameters in microalbumiuric patients with essential hypertension</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">4 weeks</th><th align="center" rowspan="1" colspan="1">8 weeks</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Serum creatinine (mg/dl)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">0.88 &#x000b1; 0.13</td><td align="center" rowspan="1" colspan="1">0.87 &#x000b1; 0.20</td><td align="center" rowspan="1" colspan="1">0.86 &#x000b1; 0.15</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(0.58-1.02)</td><td align="center" rowspan="1" colspan="1">(0.56-1.07)</td><td align="center" rowspan="1" colspan="1">(0.58-1.03)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">0.96 &#x000b1; 0.22</td><td align="center" rowspan="1" colspan="1">0.91 &#x000b1; 0.15</td><td align="center" rowspan="1" colspan="1">0.90 &#x000b1; 0.14</td><td align="center" rowspan="1" colspan="1">0.130</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(0.74-1.42)</td><td align="center" rowspan="1" colspan="1">(0.72-1.06)</td><td align="center" rowspan="1" colspan="1">(0.66-1.02)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Serum soeidum (mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">141.23 &#x000b1; 6.45</td><td align="center" rowspan="1" colspan="1">141.89 &#x000b1; 5.70</td><td align="center" rowspan="1" colspan="1">139.57 &#x000b1; 5.29</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(128-152)</td><td align="center" rowspan="1" colspan="1">(129-1500</td><td align="center" rowspan="1" colspan="1">(143-148)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">139 &#x000b1; 5.42</td><td align="center" rowspan="1" colspan="1">140.57 &#x000b1; 5.09</td><td align="center" rowspan="1" colspan="1">138.45 &#x000b1; 3.52</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(129-144)</td><td align="center" rowspan="1" colspan="1">(132-150)</td><td align="center" rowspan="1" colspan="1">(129-140)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Serum potassium (mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">3.93 &#x000b1; 0.49</td><td align="center" rowspan="1" colspan="1">3.77 &#x000b1; 0.52</td><td align="center" rowspan="1" colspan="1">3.88 &#x000b1; 0.58</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(3.2-5.0)</td><td align="center" rowspan="1" colspan="1">(3.0-4.2)</td><td align="center" rowspan="1" colspan="1">(3.2-4.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">4.11 &#x000b1; 0.59</td><td align="center" rowspan="1" colspan="1">3.90 &#x000b1; 0.58</td><td align="center" rowspan="1" colspan="1">4.12 &#x000b1; 0.67</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(3.2-4.81)</td><td align="center" rowspan="1" colspan="1">(3.0-4.8)</td><td align="center" rowspan="1" colspan="1">(3.2-4.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urinary sodium (mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">143.94 &#x000b1; 11.73</td><td align="center" rowspan="1" colspan="1">143.46 &#x000b1; 10.39</td><td align="center" rowspan="1" colspan="1">146.52 &#x000b1; 11.90</td><td align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(121-156)</td><td align="center" rowspan="1" colspan="1">(118-145)</td><td align="center" rowspan="1" colspan="1">(132-162)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">142.85 &#x000b1; 11.70</td><td align="center" rowspan="1" colspan="1">144.52 &#x000b1; 6.35</td><td align="center" rowspan="1" colspan="1">144.30 &#x000b1; 8.40</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(125-160)</td><td align="center" rowspan="1" colspan="1">(135-153)</td><td align="center" rowspan="1" colspan="1">(129-155)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urinary potassium (mmol/L)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amlodipine group (n = 60)</td><td align="center" rowspan="1" colspan="1">46.80 &#x000b1; 14.14</td><td align="center" rowspan="1" colspan="1">47.24 &#x000b1; 5.74</td><td align="center" rowspan="1" colspan="1">50.24 &#x000b1; 7.35</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(29-56)</td><td align="center" rowspan="1" colspan="1">(40-56)</td><td align="center" rowspan="1" colspan="1">(39-60)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lisinopril group (n = 60)</td><td align="center" rowspan="1" colspan="1">49.24 &#x000b1; 8.84</td><td align="center" rowspan="1" colspan="1">47.91 &#x000b1; 8.61</td><td align="center" rowspan="1" colspan="1">52.69 &#x000b1; 9.62</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(38-64)</td><td align="center" rowspan="1" colspan="1">(38-60)</td><td align="center" rowspan="1" colspan="1">(30-90)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as mean &#x000b1; SD; Figures in parentheses indicate range; Amlodepin <italic>vs.</italic>lisinopril group: <italic>P</italic> value for all parameters at base line, four and eight weeks &#x0003e; 0.08 (not significant)</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0005" position="float"><label>Table 5</label><caption><p>Effect of 4 and 8 weeks treatment with amlodipine and lisonopril on creatinine clearlance and urinary albumin excretion in essential hypertension patients with microalbuminuria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">4 weeks</th><th align="center" rowspan="1" colspan="1">8 weeks</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ClCr (ml/min)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Amlodipine group (n60)</td><td align="center" rowspan="1" colspan="1">93.98 &#x000b1; 6.40</td><td align="center" rowspan="1" colspan="1">93.43 &#x000b1; 5.97</td><td align="center" rowspan="1" colspan="1">92.46 &#x000b1; 6.81</td><td align="center" rowspan="1" colspan="1">0.214</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(85-103)</td><td align="center" rowspan="1" colspan="1">(85-102)</td><td align="center" rowspan="1" colspan="1">(83-103)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">&#x02003;Lisinopril group (n60)</td><td align="center" rowspan="1" colspan="1">93.21 &#x000b1; 7.49</td><td align="center" rowspan="1" colspan="1">92.96 &#x000b1; 7.30</td><td align="center" rowspan="1" colspan="1">93.90 &#x000b1; 8.06</td><td align="center" rowspan="1" colspan="1">0.6307</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(83-105.1)</td><td align="center" rowspan="1" colspan="1">(84-102)</td><td align="center" rowspan="1" colspan="1">(83.1-106.81)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> 0.5497</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> 0.7027</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> 0.2968</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">UAE (mg/24 hr)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">&#x02003;Lisinopril group (n60)</td><td align="center" rowspan="1" colspan="1">79.3 &#x000b1; 3.74<xref ref-type="table-fn" rid="TF0002">*</xref></td><td align="center" rowspan="1" colspan="1">62.03 &#x000b1; 3.61<xref ref-type="table-fn" rid="TF0002">*</xref></td><td align="center" rowspan="1" colspan="1">52.02 &#x000b1; 3.05<xref ref-type="table-fn" rid="TF0002">*</xref></td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(35.9-120.2)</td><td align="center" rowspan="1" colspan="1">(35.9-120.2)</td><td align="center" rowspan="1" colspan="1">(32.2-110.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">&#x02003;Amlodipine group (n60)</td><td align="center" rowspan="1" colspan="1">73.96 &#x000b1; 4.10<xref ref-type="table-fn" rid="TF0002">*</xref></td><td align="center" rowspan="1" colspan="1">72.39 &#x000b1; 3.74<xref ref-type="table-fn" rid="TF0002">*</xref></td><td align="center" rowspan="1" colspan="1">66.12 &#x000b1; 3.94<xref ref-type="table-fn" rid="TF0002">*</xref></td><td align="center" rowspan="1" colspan="1">0.1742</td></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(38.7-131.1)</td><td align="center" rowspan="1" colspan="1">(38.7-131)</td><td align="center" rowspan="1" colspan="1">(38.1-132)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>P</italic> 0.3420</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c;0.047</td><td align="center" rowspan="1" colspan="1"><italic>P</italic> &#x0003c;0.0059</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF0002"><label>*</label><p>Standard error of mean; Data expressed as mean &#x000b1; SD; Figures in parentheses indicate range</p></fn></table-wrap-foot></table-wrap><p>There was a significant reduction in UAE rate after four and eight weeks of treatment with lisinopril, compared to baseline value (<italic>P</italic> = 0.0000). In amlodipine group, there was no significant reduction in UAE rate after four and eight weeks of therapy compared to baseline value (<italic>P</italic> &#x0003e; 0.1742) [<xref ref-type="table" rid="T0005">Table 5</xref>].</p><p>We observed significant reduction of UAE rate in lisinopril group after four weeks (<italic>P</italic> &#x0003c; 0.04) and eight weeks (<italic>P</italic> &#x0003c; 0.005) of therapy compared to that of amlodipine group [<xref ref-type="table" rid="T0005">Table 5</xref>].</p></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>The passage of various substances including albumin, through the glomerulus, not only depends upon their molecular size, electrical charge, and shape but also to the size and selective properties of the glomerular filtrate. Renal hemodynamics also plays an important role.[<xref ref-type="bibr" rid="CIT17">17</xref>] The transport of albumin across the glomerular filter is influenced by the variations in the glomerular hemodynamics seen in essential hypertension. In fact, the renal alterations that accompany arterial hypertension are characterized by an increase in renal vascular resistance, a decrease in renal flow, and the initial retention of glumerular filtrate which will tend to diminish only at a later stage. The slight alteration in the glomerular filtrate is probably caused by vasoconstriction of the efferent arteriole, which in turn is responsible for intraglomerular hypertension and for the increased filtration fraction.[<xref ref-type="bibr" rid="CIT18">18</xref>] This process is definitely regulated by neurohormonal mechanisms such as the vascular response to the noradrenaline and angiotensin.[<xref ref-type="bibr" rid="CIT19">19</xref>] Therefore, it is highly probable that through vasoconstriction efferent arteriole,angiotensin II increases the hydrostatic pressure in the glomerular capillaries to retain the glomerular filtrate, which results, however, in an even greater filtration of proteins. Therefore, the proteinuria could be a result not only of structural modifications of the glomeruli but also of these hemodynamic alterations.</p><p>Theoretically, proteinuria, in the subject with hypertension, can be diminished by way of regression of the structural renal alterations or modifications of the hemodynamics of the afferent arteriole, glomerulus, efferent arteriole system or through mechanisms that re-establish normal glomerular permeability.[<xref ref-type="bibr" rid="CIT20">20</xref>] The results of our study clearly demonstrate that despite similar antihypertensive efficacy, lisinopril but not the amlodipine, reduced UAE significantly in patients with EHT and microalbuminuria. These observations are consistent with previous studies.[<xref ref-type="bibr" rid="CIT21">21</xref><xref ref-type="bibr" rid="CIT22">22</xref>] Amlodipine has also been compared to eplerinone&#x02014;a selective aldosterone blocker&#x02014;in patients with systolic hypertension and found inferior in reducing microalbuminuria (10% <italic>vs.</italic> 52%) despite good and comparable blood pressure control.[<xref ref-type="bibr" rid="CIT23">23</xref>]</p><p>In previous studies conducted both on animals and human, ACE inhibitors were shown to be able to reduce urinary excretion of proteins in various types of renal disease including those associated with diabetes.[<xref ref-type="bibr" rid="CIT8">8</xref><xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT24">24</xref>] The mechanisms by which ACE inhibitors confer a beneficial effect on proteinuria reduction are largely unknown. The systemic arterial pressure can play an important role by reducing the filtration pressure. However, no correlation has been observed between antihypertensive activity and the effects on proteinuria.[<xref ref-type="bibr" rid="CIT16">16</xref>] Furthermore, the reduction in albumin excretion that we observed after lisinopril does not seem to be necessarily connected to the antihypertensive properties of the drug because amlodipine, which has the same antihypertensive activity and even better control of DBP and MAP than lisinopril, had no significant effect on microalbuminuria. Various mechanisms have been proposed to explain the beneficial effects of ACE inhibitors on proteinuria. The first is that this phenomenon might be due to the improvement in intrarenal hemodynamics. The second mechanism is that this category of drugs can reduce the permeability of the basement membrane of the glomerulus. The first hypothesis derives primarily from studies that show how ACE inhibitors diminish proteinuria, the renal filtration fraction, and the intraglomerular pressure in various experimental models of renal disease.[<xref ref-type="bibr" rid="CIT24">24</xref><xref ref-type="bibr" rid="CIT25">25</xref>] Since angiotensin II increases the tone of the efferent arteriole, the intraglomerular pressure, and the proteinuria, it is conceivable that ACE inhibitors can reduce the proteinuria by inhibiting the effect of angiotensin II in renal microcirculation. Furthermore, some experts have recently affirmed that ACE inhibitors can diminish proteinuria by reducing the permeability of the basement membrane of the glomerulus.[<xref ref-type="bibr" rid="CIT26">26</xref>]</p><p>Microalbuminuria in EHT reflects systemic dysfunction of vascular endothelium, a structure intimately involved in the permeability, hemostasis, fibrinolysis, and blood pressure control. Inhibition of angiotensin II conversion and preservation of nitric oxide production are considered to underlie the favorable effects of ACE inhibition on endothelial function and potentially on cardiovascular events. Both angiotensinII and nitric oxide are involved in the balance of thrombosis, and fibrinolysis, via changes in platelet aggregation plasminogen activator, as well as changes in the matrix synthesis of plaques.[<xref ref-type="bibr" rid="CIT27">27</xref><xref ref-type="bibr" rid="CIT28">28</xref>] Hence, it is conceivable that reduction in microalbuminuria by ACE inhibitor is likely due to its favorable effect on vascular endothelium.</p><p>We did not observe any significant modifications in microlbuminuria with amlodipine. Calcium acts as a second messenger to mediate the vasoconstriction effect of angiotensin and nor epinephrine. If, in subjects with hypertension, the efferent arteriole is further constricted by these hormonal regulators, then a positive response by calcium antagonists appears justified. The modifications of hemodynamics with calcium antagonists are related to different factors, such as, the type of calcium antagonist, the way in which it is administered, basal vascular tone, and the basal levels of vasoconstrictors, such as angiotensin II.[<xref ref-type="bibr" rid="CIT10">10</xref>] In this study, amlodipine administered orally did not alter UAE significantly. This might be attributable either to poor selectivity of the drug for renal vessels or to the fact that in these patients the drug acted more on the afferent arteriole than on efferent arteriole leaving the intraglomerular hypertension unchanged furthermore, it seems unlikely that it can act on the permeability of the basement membrane, given the total absence of significant changes in the UAE.</p><p>We did not observe any change in creatinine clearance in hypertensive patients treated with lisinopril or amlodipine. Similar results have been observed in the past.[<xref ref-type="bibr" rid="CIT21">21</xref><xref ref-type="bibr" rid="CIT29">29</xref>]</p><p>Since microalbuminuria in EHT reflects systemic vascular endothelial dysfunction, its reduction by ACE inhibitor lisinopril points towards the favorable effects of ACE inhibition on vascular endothelium. Recently, HOPE trial has also revealed beneficial effects of ACE inhibitors on vascular endothelium resulting in reduction of cardiovascular morbidity and mortality.[<xref ref-type="bibr" rid="CIT30">30</xref>] The implications of this observation on cardiovascular mortality and morbidity, and in future, progression of renal disease in patients with EHT remain to be established.</p><p>In conclusion, this study has shown that eight weeks of therapy with lisinopril reduces UAE in patients with mild to moderate EHT, whereas amlodipine had no measurable effect on UAE, despite similar antihypertensive efficacy.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="CIT1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigazzi</surname><given-names>R</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Campese</surname><given-names>VM</given-names></name><name><surname>Baldari</surname><given-names>G</given-names></name></person-group><article-title>Prevalence of mocroalbuminuria in a large population of patients with mild to moderate essential hypertension</article-title><source>Nephron</source><year>1992</year><volume>61</volume><fpage>94</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1528348</pub-id></element-citation></ref><ref id="CIT2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalal</surname><given-names>S</given-names></name><name><surname>Sofi</surname><given-names>FA</given-names></name><name><surname>Alai</surname><given-names>MS</given-names></name><name><surname>Siddiqqi</surname><given-names>MA</given-names></name><name><surname>Bhat</surname><given-names>MA</given-names></name><name><surname>Khan</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Prevalence of microalbuminuria in essential hypertension: A study of patients with mild to moderate hypertension</article-title><source>Indian J Nephrol</source><year>2001</year><volume>11</volume><fpage>6</fpage><lpage>11</lpage></element-citation></ref><ref id="CIT3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Evrin</surname><given-names>PE</given-names></name></person-group><article-title>Increased urinary albumin excretion in benign essential hypertension</article-title><source>Lancet</source><year>1974</year><volume>1</volume><fpage>231</fpage><lpage>7</lpage></element-citation></ref><ref id="CIT4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Losito</surname><given-names>A</given-names></name><name><surname>Fortunati</surname><given-names>F</given-names></name><name><surname>Zampi</surname><given-names>I</given-names></name><name><surname>Del Favero</surname><given-names>A</given-names></name></person-group><article-title>Impaired functional reserve and albuminuria in essential hypertension</article-title><source>Br Med J</source><year>1988</year><volume>1</volume><fpage>1562</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">3135009</pub-id></element-citation></ref><ref id="CIT5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giaconi</surname><given-names>S</given-names></name><name><surname>Levanti</surname><given-names>C</given-names></name><name><surname>Fommei</surname><given-names>E</given-names></name><name><surname>Innocenti</surname><given-names>F</given-names></name><name><surname>Seghieri</surname><given-names>G</given-names></name><name><surname>Palla</surname><given-names>L</given-names></name><etal/></person-group><article-title>Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild hypertension</article-title><source>Am J Hypertens</source><year>1989</year><volume>2</volume><fpage>259</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">2706093</pub-id></element-citation></ref><ref id="CIT6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Bigazzi</surname><given-names>R</given-names></name><name><surname>Baldari</surname><given-names>G</given-names></name><name><surname>Campese</surname><given-names>VM</given-names></name></person-group><article-title>Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs</article-title><source>Am J Med</source><year>1992</year><volume>93</volume><fpage>525</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1442855</pub-id></element-citation></ref><ref id="CIT7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yudkin</surname><given-names>JS</given-names></name><name><surname>Forrest</surname><given-names>RD</given-names></name><name><surname>Jackson</surname><given-names>CA</given-names></name></person-group><article-title>Microalbuminuria as a predictor of vascular disease in non-diabetic subjects</article-title><source>Lancet</source><year>1988</year><volume>2</volume><fpage>530</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">2900920</pub-id></element-citation></ref><ref id="CIT8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Leblane</surname><given-names>H</given-names></name><name><surname>Suarez</surname><given-names>L</given-names></name><name><surname>Guyenne</surname><given-names>TT</given-names></name><name><surname>Menard</surname><given-names>J</given-names></name><name><surname>Passa</surname><given-names>P</given-names></name></person-group><article-title>Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria</article-title><source>BMJ</source><year>1987</year><volume>294</volume><fpage>1448</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">3038254</pub-id></element-citation></ref><ref id="CIT9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reams</surname><given-names>GP</given-names></name><name><surname>Bauer</surname><given-names>JH</given-names></name></person-group><article-title>Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction</article-title><source>Arch Intern Med</source><year>1986</year><volume>146</volume><fpage>2145</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3022660</pub-id></element-citation></ref><ref id="CIT10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakris</surname><given-names>GL</given-names></name></person-group><article-title>Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus</article-title><source>Ann Intern Med</source><year>1990</year><volume>113</volume><fpage>987</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2240922</pub-id></element-citation></ref><ref id="CIT11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickish</surname><given-names>O</given-names></name><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Mann</surname><given-names>JF</given-names></name><name><surname>Helder</surname><given-names>T</given-names></name><name><surname>Bergen</surname><given-names>F</given-names></name><name><surname>Rauterberg</surname><given-names>EW</given-names></name><etal/></person-group><article-title>Calcium antagonisteu bei chronischer Niereu Suffizions</article-title><source>Dtsch Med WO Chenschr</source><year>1988</year><volume>113</volume><fpage>1546</fpage><lpage>8</lpage></element-citation></ref><ref id="CIT12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferdes</surname><given-names>L</given-names></name><name><surname>Daccordi</surname><given-names>HA</given-names></name><name><surname>Martello</surname><given-names>M</given-names></name><name><surname>Marisa</surname><given-names>P</given-names></name><name><surname>Inserra</surname><given-names>F</given-names></name></person-group><article-title>ACE inhibitors versus calcium channel antagonists in the treatment of diabetic hypertensive patients</article-title><source>Hypertension</source><year>1991</year><volume>17</volume><fpage>453</fpage></element-citation></ref><ref id="CIT13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Murabayashi</surname><given-names>S</given-names></name><name><surname>Takebe</surname><given-names>K</given-names></name></person-group><article-title>Comparison of the renal effects of ACE inhibitor and calcium antagonist in hypertensive type 2 (non-insulin dependent) diabetic patients will microalbuminuria in a randomized, controlled trial</article-title><source>Diabetalgia</source><year>1989</year><volume>32</volume><fpage>40</fpage><lpage>4</lpage></element-citation></ref><ref id="CIT14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stornello</surname><given-names>M</given-names></name><name><surname>Valvo</surname><given-names>EV</given-names></name><name><surname>Scapellato</surname><given-names>L</given-names></name></person-group><article-title>Hemodynamic, renal and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captropril in hypertensive type II diabetic patients with nephropathy</article-title><source>J Cardiovasc Pharmacol</source><year>1989</year><volume>14</volume><fpage>851</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2481772</pub-id></element-citation></ref><ref id="CIT15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>JH</given-names></name><name><surname>Reems</surname><given-names>GP</given-names></name></person-group><article-title>Do calcium antagonists protect the human hypertensive kidney?</article-title><source>Am J Hypertens</source><year>1989</year><volume>2</volume><fpage>173</fpage><lpage>8</lpage></element-citation></ref><ref id="CIT16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Bigazzi</surname><given-names>R</given-names></name><name><surname>Baldari</surname><given-names>G</given-names></name><name><surname>Campese</surname><given-names>VM</given-names></name></person-group><article-title>Microalbuminuria in patients with essential hypertensive: Effect of an angiotensin converting enzyme inhibitor and of a calcium channel blocker</article-title><source>Am J Hypertens</source><year>1991</year><volume>4</volume><fpage>291</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2059393</pub-id></element-citation></ref><ref id="CIT17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>VW</given-names></name><name><surname>Robinson</surname><given-names>RR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Seldin</surname><given-names>VW</given-names></name><name><surname>Giebisch</surname></name></person-group><article-title>Proteinuria</article-title><source>The kidney: Physiology and pathophysiology</source><year>1985</year><publisher-loc>New York</publisher-loc><publisher-name>Raven Press</publisher-name></element-citation></ref><ref id="CIT18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungman</surname><given-names>S</given-names></name><name><surname>Aurell</surname><given-names>M</given-names></name><name><surname>Hartford</surname><given-names>M</given-names></name><name><surname>Wikstrand</surname><given-names>J</given-names></name><name><surname>Wilhelmsen</surname><given-names>L</given-names></name><name><surname>Berglund</surname><given-names>G</given-names></name></person-group><article-title>Blood pressure and renal functions</article-title><source>Acta Med Scand</source><year>1980</year><volume>208</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">7435244</pub-id></element-citation></ref><ref id="CIT19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayers</surname><given-names>BD</given-names></name><name><surname>Deen</surname><given-names>WM</given-names></name><name><surname>Brenner</surname><given-names>BM</given-names></name></person-group><article-title>Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in rat</article-title><source>Circ Res</source><year>1975</year><volume>37</volume><fpage>101</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">1149180</pub-id></element-citation></ref><ref id="CIT20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deen</surname><given-names>WM</given-names></name><name><surname>Satvat</surname><given-names>B</given-names></name></person-group><article-title>Determinants of the glomerular filtration of proteins</article-title><source>Am J Physiol</source><year>1981</year><volume>241</volume><fpage>I62</fpage><lpage>70</lpage></element-citation></ref><ref id="CIT21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raineri</surname><given-names>G</given-names></name><name><surname>Andriani</surname><given-names>A</given-names></name><name><surname>Lamontaneva</surname><given-names>G</given-names></name><name><surname>DeCesaris</surname><given-names>R</given-names></name></person-group><article-title>Effects of lisinopril and amlodipine on microalbuminuria and renal functions in patients with hypertension</article-title><source>Clin Pharmacol Ther</source><year>1994</year><volume>56</volume><fpage>323</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7924128</pub-id></element-citation></ref><ref id="CIT22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alli</surname><given-names>C</given-names></name><name><surname>Lombardo</surname><given-names>M</given-names></name><name><surname>Zanni</surname><given-names>D</given-names></name><name><surname>Agrati</surname><given-names>AM</given-names></name><name><surname>Cassani</surname><given-names>M</given-names></name><name><surname>Granata</surname><given-names>S</given-names></name></person-group><article-title>Albuminuria and transferrinuria in essential hypertension: Effects of antihypertensive therapy</article-title><source>Am J Hypertens</source><year>1996</year><volume>9</volume><fpage>1068</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8931831</pub-id></element-citation></ref><ref id="CIT23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Duprez</surname><given-names>D</given-names></name><name><surname>St Hillaire</surname><given-names>R</given-names></name><name><surname>Krause</surname><given-names>S</given-names></name><name><surname>Roniker</surname><given-names>B</given-names></name><name><surname>Kuse-Hamilton</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of selective aldosterone blocker eplerinone versus the calcium channel antagonist, amlodipine in systolic hypertension</article-title><source>Hypertension</source><year>2003</year><volume>41</volume><fpage>1021</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12682082</pub-id></element-citation></ref><ref id="CIT24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cesaris</surname><given-names>R</given-names></name><name><surname>Ranieri</surname><given-names>G</given-names></name><name><surname>Filitti</surname><given-names>V</given-names></name><name><surname>Andriani</surname><given-names>A</given-names></name><name><surname>Bonfantino</surname><given-names>MV</given-names></name></person-group><article-title>Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients</article-title><source>J Cardiovasc Pharmacol</source><year>1993</year><volume>22</volume><fpage>208</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">7692159</pub-id></element-citation></ref><ref id="CIT25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeg</surname><given-names>IE</given-names></name><name><surname>De Long</surname><given-names>PE</given-names></name><name><surname>van der Hem</surname><given-names>GK</given-names></name><name><surname>de Zeeuw</surname><given-names>D</given-names></name></person-group><article-title>Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril</article-title><source>Kidney Int</source><year>1989</year><volume>36</volume><fpage>272</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2550696</pub-id></element-citation></ref><ref id="CIT26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murelli</surname><given-names>E</given-names></name><name><surname>Loon</surname><given-names>N</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Peters</surname><given-names>W</given-names></name><name><surname>Myers</surname><given-names>BD</given-names></name></person-group><article-title>Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy</article-title><source>Diabetes</source><year>1990</year><volume>39</volume><fpage>2</fpage><lpage>8</lpage></element-citation></ref><ref id="CIT27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzau</surname><given-names>VI</given-names></name></person-group><article-title>Angiotensin converting enzyme as a multimechanistic factor in CAD</article-title><source>J Myocard Ischemia</source><year>1995</year><volume>7</volume><fpage>6</fpage><lpage>14</lpage></element-citation></ref><ref id="CIT28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cody</surname><given-names>RJ</given-names></name></person-group><article-title>The integrated effects of Angiotensin II</article-title><source>Am J Cardiol</source><year>1997</year><volume>79</volume><fpage>9</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9127615</pub-id></element-citation></ref><ref id="CIT29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanetti-Elshater</surname><given-names>F</given-names></name><name><surname>Pingitore</surname><given-names>R</given-names></name><name><surname>Beretta-Piecoli</surname><given-names>C</given-names></name><name><surname>Riesen</surname><given-names>W</given-names></name><name><surname>Heinen</surname><given-names>G</given-names></name></person-group><article-title>Calcium antagonists for treatment of diabetes associated hypertension: Metabolic and renal effects of amlodipine</article-title><source>Am J Hypertens</source><year>1994</year><volume>7</volume><fpage>36</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">8136109</pub-id></element-citation></ref><ref id="CIT30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinert</surname><given-names>S</given-names></name></person-group><article-title>HOPE for cardiovascular disease prevention with ACE inhibitor, ramipril: Heart outcomes prevention evaluation</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>841</fpage><pub-id pub-id-type="pmid">10485736</pub-id></element-citation></ref></ref-list></back></article>